title: Development of theophylline floating microballoons using cellulose acetate butyrate and/or Eudragit RL 100 polymers with different permeability characteristics.
abstract: The objective of the present investigation was to design a sustained release floating microcapsules of theophylline using two polymers of different permeability characteristics; Eudragit RL 100 (Eu RL) and cellulose acetate butyrate (CAB) using the oil-in-oil emulsion solvent evaporation method. Polymers were used separately and in combination to prepare different microcapsules. The effect of drug-polymer interaction was studied for each of the polymers and for their combination. Encapsulation efficiency, the yield, particle size, floating capability, morphology of microspheres, powder X-ray diffraction analysis (XRD), and differential scanning calorimetry (DSC) were evaluated. The in vitro release studies were performed in PH 1.2 and 7.4. The optimized drug to polymer ratios was found to be 4:1 (F(2)) and 0.75:1 (F'(2)) with Eu RL and CAB, respectively. The best drug to polymer ratio in mix formulation was 4:1:1 (theophylline: Eu RL: CAB ratio). Production yield, loading efficiencies, and particle size of F(2) and F'(2) were found to be 59.14% and 45.39%, 73.93% and 95.87%, 372 and 273 micron, respectively. Microsphere prepared with CAB showed the best floating ability (80.3 ± 4.02% buoyancy) in 0.1 M HCl for over 12 h. The XRD and DSC showed that theophylline in the drug loaded microspheres was stable and in crystaline form. Microparticles prepared using blend of Eu RL and CAB polymers indicated more sustained pattern than the commercial tablet (P<0.05). Drug loaded floating microballoons prepared of combination of Eu RL and CAB with 1:1 ratio were found to be a suitable delivery system for sustained release delivery of theophylline which contained lower amount of polymer contents in the microspheres.
authors: Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz; I.R.Iran.
authors: M
authors: M
authors: Jelvehgari
authors: M
authors: M
authors: Maghsoodi
authors: H
authors: H
authors: Nemati
references: J Control Release. 1999 Mar 8;58(1):9-20
references: 10021485
references: J Pharm Sci. 1986 Jun;75(6):573-8
references: 3735102
references: J Control Release. 2002 Feb 19;79(1-3):71-9
references: 11853919
references: PDA J Pharm Sci Technol. 1995 Jan-Feb;49(1):13-9
references: 7757453
references: J Pharm Sci. 1992 Feb;81(2):135-40
references: 1372046
references: J Pharm Pharmacol. 1993 Jan;45(1):21-4
references: 8094440
references: J Microencapsul. 1995 Jan-Feb;12(1):71-81
references: 7730959
references: Int J Pharm. 2002 Jul 25;241(2):279-92
references: 12100855
references: J Microencapsul. 1998 Nov-Dec;15(6):725-37
references: 9818950
references: Int J Pharm. 2003 Feb 18;252(1-2):99-109
references: 12550785
references: Eur J Pharm Biopharm. 2003 May;55(3):297-304
references: 12754004
references: J Microencapsul. 2002 Nov-Dec;19(6):811-22
references: 12569029
references: Drug Metab Rev. 2001 May;33(2):149-60
references: 11495501
references: Br J Clin Pharmacol. 1985;19 Suppl 2:77S-83S
references: 3890912
references: J Microencapsul. 1995 Jul-Aug;12(4):417-23
references: 8583316
references: J Microencapsul. 2000 May-Jun;17(3):373-83
references: 10819424
references: J Biomater Sci Polym Ed. 1997;8(6):457-66
references: 9151193
references: J Microencapsul. 1999 Nov-Dec;16(6):715-29
references: 10575624
references: Acta Pharm. 2005 Sep;55(3):277-85
references: 16375838
references: Eur J Pharm Biopharm. 1998 Jan;45(1):75-82
references: 9689538